E. Jaffe, . Hn, and H. Stein, Vardiman JW World Health Organization classification of tumours. Pathology and genetics, tumours of haematopoietic and lymphoid tissues, 2001.

P. Kanavaros, M. Lescs, J. Briere, M. Divine, and F. Galateau, Joab I Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus, Blood, vol.81, pp.2688-2695, 1993.

P. Kanavaros, J. Briere, J. Emile, P. Gaulard, and . Epstein, Barr virus in T and natural killer (NK) cell non-Hodgkin s lymphomas ', Leukemia, vol.10, issue.2, pp.84-87, 1996.

C. Bossard, K. Belhadj, F. Reyes, N. Martin-garcia, F. Berger et al., Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials, Blood, vol.109, issue.5, pp.2183-2189, 2007.
DOI : 10.1182/blood-2006-07-033142

L. Quintanilla-martinez, M. Kremer, G. Keller, M. Nathrath, and A. Gamboa-dominguez, p53 Mutations in Nasal Natural Killer/T-Cell Lymphoma from Mexico, The American Journal of Pathology, vol.159, issue.6, pp.2095-2105, 2001.
DOI : 10.1016/S0002-9440(10)63061-1

T. Takakuwa, Z. Dong, S. Nakatsuka, S. Kojya, and Y. Harabuchi, Frequent mutations of Fas gene in nasal NK/T cell lymphoma, Oncogene, vol.21, issue.30, pp.4702-4705, 2002.
DOI : 10.1038/sj.onc.1205571

M. Takahara, K. Kishibe, N. Bandoh, S. Nonaka, Y. Harabuchi et al., P53, N- and K-Ras, and ??-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan, Human Pathology, vol.35, issue.1, pp.86-95, 2004.
DOI : 10.1016/j.humpath.2003.08.025

Y. Jeon, H. Kim, S. Park, H. Choi, and Y. Kim, Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma, Laboratory Investigation, vol.276, issue.7, pp.874-884, 2005.
DOI : 10.1038/labinvest.3700291

K. Aozasa, T. Takakuwa, T. Hongyo, W. Yang, and N. Nasal, Nasal NK/T-cell lymphoma: epidemiology and pathogenesis, International Journal of Hematology, vol.108, issue.Suppl, pp.110-117, 2008.
DOI : 10.1007/s12185-008-0021-7

M. Yamaguchi, K. Kita, H. Miwa, K. Nishii, and K. Oka, Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells, Cancer, vol.81, issue.11, pp.2351-2356, 1995.
DOI : 10.1002/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1

S. Zhao, Q. Tang, M. He, F. Yang, and H. Wang, A novel nude mice model of human extranodal nasal type NK/T-cell lymphoma, Leukemia, vol.12, issue.1, pp.170-178, 2008.
DOI : 10.1038/sj.leu.2404945

J. Tsuchiyama, T. Yoshino, M. Mori, E. Kondoh, and T. Oka, Akagi T Characterization of a novel human natural killer cell line (NK-YS) established from natural killer cell ? lymphoma/leukemia associated with Epstein-Barr virus infection, Blood, vol.92, pp.1374-1383, 1998.

Y. Kagami, S. Nakamura, R. Suzuki, S. Iida, Y. Yatabe et al., Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3e+, CD56+ phenotype and associated with the Epstein-Barr virus, British Journal of Haematology, vol.98, issue.3, pp.669-677, 1998.
DOI : 10.1046/j.1365-2559.1996.278324.x

M. Yagita, C. Huang, H. Umehara, Y. Matsuo, R. Tabata et al., A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation, Leukemia, vol.14, issue.5, pp.922-930, 2000.
DOI : 10.1038/sj.leu.2401769

H. Nagata, A. Konno, N. Kimura, Y. Zhang, and M. Kimura, Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T/NK-cell lymphomas associated with the Epstein-Barr virus, Blood, vol.97, issue.3, pp.708-713, 2001.
DOI : 10.1182/blood.V97.3.708

H. Drexler and Y. Matsuo, Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia???lymphoma, Leukemia, vol.14, issue.5, pp.777-782, 2000.
DOI : 10.1038/sj.leu.2401778

M. Benekli, M. Baer, and H. Baumann, Signal transducer and activator of transcription proteins in leukemias, Blood, vol.101, issue.8, pp.2940-2954, 2003.
DOI : 10.1182/blood-2002-04-1204

J. Bromberg, M. Wrzeszczynska, G. Devgan, Y. Zhao, and R. Pestell, Stat3 as an Oncogene, Cell, vol.98, issue.3, pp.295-303, 1999.
DOI : 10.1016/S0092-8674(00)81959-5

URL : http://doi.org/10.1016/s0092-8674(00)81959-5

T. Bowman, R. Garcia, J. Turkson, R. Jove, and . Stats-in-oncogenesis, STATs in oncogenesis, Oncogene, vol.19, issue.21, pp.2474-2488, 2000.
DOI : 10.1038/sj.onc.1203527

D. Levy and C. Lee, What does Stat3 do?, Journal of Clinical Investigation, vol.109, issue.9, pp.1143-1148, 2002.
DOI : 10.1172/JCI0215650

A. Zamo, R. Chiarle, R. Piva, J. Howes, Y. Fan et al., Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death, Oncogene, vol.21, issue.7, pp.1038-1047, 2002.
DOI : 10.1038/sj.onc.1205152

Q. Zhang, P. Raghunath, L. Xue, M. Majewski, and D. Carpentieri, Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma, The Journal of Immunology, vol.168, issue.1, pp.466-474, 2002.
DOI : 10.4049/jimmunol.168.1.466

R. Chiarle, W. Simmons, H. Cai, G. Dhall, and A. Zamo, Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target, Nature Medicine, vol.261, issue.6, pp.623-629, 2005.
DOI : 10.1084/jem.190.10.1451

B. Aggarwal, G. Sethi, K. Ahn, S. Sandur, and M. Pandey, Targeting Signal-Transducer-and-Activator-of-Transcription-3 for Prevention and Therapy of Cancer, Annals of the New York Academy of Sciences, vol.3, issue.6, pp.151-169, 2006.
DOI : 10.1196/annals.1378.063

H. Drexler and Y. Matsuo, Guidelines for the characterization and publication of human malignant hematopoietic cell lines, Leukemia, vol.13, issue.6, pp.835-842, 1999.
DOI : 10.1038/sj.leu.2401428

S. Nguyen, N. Dhedin, J. Vernant, M. Kuentz, A. Jijakli et al., NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect, Blood, vol.105, issue.10, pp.4135-4142, 2005.
DOI : 10.1182/blood-2004-10-4113

E. Clave, V. Rocha, K. Talvensaari, M. Busson, and C. Douay, Prognostic value of pretransplantation host thymic function in HLA-identical sibling hematopoietic stem cell transplantation, Blood, vol.105, issue.6, pp.2608-2613, 2005.
DOI : 10.1182/blood-2004-04-1667

C. Chen, F. Hsieh, J. Lieblein, J. Brown, C. Chan et al., Stat3 activation in human endometrial and cervical cancers, British Journal of Cancer, vol.57, issue.4, pp.591-599, 2007.
DOI : 10.1126/science.8140422

K. Livak and T. Schmittgen, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2???????CT Method, Methods, vol.25, issue.4, pp.402-408, 2001.
DOI : 10.1006/meth.2001.1262

M. Cooper, T. Fehniger, and M. Caligiuri, The biology of human natural killer-cell subsets, Trends in Immunology, vol.22, issue.11, pp.633-640, 2001.
DOI : 10.1016/S1471-4906(01)02060-9

G. Niu, K. Wright, M. Huang, L. Song, E. Haura et al., Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis, Oncogene, vol.21, issue.13, pp.2000-2008, 2002.
DOI : 10.1038/sj.onc.1205260

J. Yoo, D. Huso, D. Nathans, and S. Desiderio, Specific Ablation of Stat3?? Distorts the Pattern of Stat3-Responsive Gene Expression and Impairs Recovery from Endotoxic Shock, Cell, vol.108, issue.3, pp.331-344, 2002.
DOI : 10.1016/S0092-8674(02)00636-0

H. Niwa, T. Burdon, and I. Chambers, Self-renewal of pluripotent embryonic stem cells is mediated via activation of??STAT3, Genes & Development, vol.12, issue.13, pp.2048-2060, 1998.
DOI : 10.1101/gad.12.13.2048

N. Harir, C. Pecquet, M. Kerenyi, K. Sonneck, and B. Kovacic, Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias, Blood, vol.109, issue.4, pp.1678-1686, 2007.
DOI : 10.1182/blood-2006-01-029918

J. Turkson, D. Ryan, J. Kim, Y. Zhang, Z. Chen et al., Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation, Journal of Biological Chemistry, vol.276, issue.48
DOI : 10.1074/jbc.M107527200

F. Garnache-ottou and J. Feuillard, Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?, British Journal of Haematology, vol.20, issue.4, pp.539-548, 2007.
DOI : 10.1182/blood-2004-09-3502

URL : https://hal.archives-ouvertes.fr/hal-00451209

M. Jordan, D. Hildeman, J. Kappler, and P. Marrack, An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder, Blood, vol.104, issue.3, pp.735-743, 2004.
DOI : 10.1182/blood-2003-10-3413

S. Hemmi, R. Bohni, G. Stark, D. Marco, and F. , A novel member of the interferon receptor family complements functionality of the murine interferon ?? receptor in human cells, Cell, vol.76, issue.5, pp.803-810, 1994.
DOI : 10.1016/0092-8674(94)90355-7

Z. Wen, Z. Zhong, and J. Darnell, Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation, Cell, vol.82, issue.2, pp.241-250, 1995.
DOI : 10.1016/0092-8674(95)90311-9

X. Zhang, J. Blenis, H. Li, and C. Schindler, Requirement of serine phosphorylation for formation of STAT-promoter complexes, Science, vol.267, issue.5206, pp.1990-1994, 1995.
DOI : 10.1126/science.7701321

Q. Zhang, H. Wang, M. Marzec, P. Raghunath, and T. Nagasawa, STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes, Proceedings of the National Academy of Sciences, vol.102, issue.19, pp.6948-6953, 2005.
DOI : 10.1073/pnas.0501959102

Q. Zhang, H. Wang, A. Woetmann, P. Raghunath, and N. Odum, STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes, Blood, vol.108, issue.3, pp.1058-1064, 2006.
DOI : 10.1182/blood-2005-08-007377

M. Narimatsu, H. Maeda, S. Itoh, T. Atsumi, T. Ohtani et al., Tissue-Specific Autoregulation of the stat3 Gene and Its Role in Interleukin-6-Induced Survival Signals in T Cells, Molecular and Cellular Biology, vol.21, issue.19, pp.6615-6625, 2001.
DOI : 10.1128/MCB.21.19.6615-6625.2001

J. Yang, M. Chatterjee-kishore, S. Staugaitis, H. Nguyen, K. Schlessinger et al., Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation, Cancer Res, vol.65, pp.939-947, 2005.

M. Boulland, V. Meignin, K. Leroy-viard, C. Copie-bergman, J. Bri-re-È et al., Human Interleukin-10 Expression in T/Natural Killer-Cell Lymphomas, The American Journal of Pathology, vol.153, issue.4, pp.1229-1237, 1998.
DOI : 10.1016/S0002-9440(10)65667-2

M. Kasprzycka, M. Marzec, X. Liu, Q. Zhang, M. Wasik et al., Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3, Proceedings of the National Academy of Sciences, vol.103, issue.26, pp.9964-9969, 2006.
DOI : 10.1073/pnas.0603507103

H. Yu, M. Kortylewski, and D. Pardoll, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nature Reviews Immunology, vol.172, issue.1, pp.41-51, 2007.
DOI : 10.1038/nri1995

O. Gires, F. Kohlhuber, E. Kilger, M. Baumann, A. Kieser et al., Latent membrane protein 1of Epstein-Barr virus interacts with JAK3 and activates STAT proteins, The EMBO Journal, vol.18, issue.11
DOI : 10.1093/emboj/18.11.3064

A. Eliopoulos and L. Young, LMP1 structure and signal transduction, Seminars in Cancer Biology, vol.11, issue.6, pp.435-444, 2001.
DOI : 10.1006/scbi.2001.0410